


# ABOUT TYRVAYA™ (varenicline solution) Nasal Spray

Tyrvaya is a prescription nasal spray indicated for the treatment of the signs and symptoms of dry eye disease. It is the **first and only nasal spray for dry eye disease** designed to activate natural tear film production in 4 weeks<sup>1</sup>.

Dry eye affects more than **38 million people** in the U.S.<sup>1,2</sup>

Tyrvaya is a whole new way to treat dry eye disease.




Tyrvaya is believed to activate the trigeminal parasympathetic pathway via the nose, resulting in increased production of basal or "natural" tear film. The exact mechanism of action is unknown at this time.<sup>3</sup>

The trigeminal parasympathetic pathway plays a role in tear film homeostasis.<sup>5</sup> Basal tear film is produced by 3 structures (lacrimal glands, meibomian glands, and goblet cells) that are innervated by the trigeminal parasympathetic pathway.<sup>5,7</sup>

## An ocular surface-sparing administration


Tyrvaya is administered once in each nostril twice daily (approximately 12 hours apart). If a dose is missed, resume regular dosing at the next scheduled dose time.

See **Instructions for Use** for step-by-step directions.<sup>3</sup>



## Studied in Patients with Mild, Moderate, and Severe Dry Eye Disease

The FDA approval of Tyrvaya is based on safety and efficacy results from the ONSET-1 and ONSET-2 clinical trials.



- ✓ Studies were **randomized, vehicle-controlled, and double-masked**<sup>3</sup>
- ✓ Studies included adults aged  $\geq 22$  years diagnosed with dry eye,<sup>3,6</sup> the **majority of patients were female (74%)**, and mean age was 61 years<sup>3</sup>
- ✓ Patients received one spray of either Tyrvaya or vehicle in each nostril **twice daily**<sup>3</sup>
- ✓ Enrolled patients had an **Eye Dryness Score (EDS) of 2-100<sup>b</sup>** and **Schirmer's Test Score (STS)  $\leq 10$  mm at baseline**<sup>3</sup>
- ✓ The use of **artificial tears was allowed** during the clinical trials<sup>3</sup>

## RESULTS

**Signs:** Tear film production was assessed using the anesthetized Schirmer's score (0-35 mm) at Week 4. Of the patients treated with Tyrvaya, 52% achieved  $\geq 10$  mm increase in Schirmer's score from baseline in the ONSET-1 study, and 47% achieved  $\geq 10$  mm increase in Schirmer's score from baseline in the ONSET-2 study, compared to 14% and 28% of vehicle-treated patients in the ONSET-1 study and the ONSET-2 study, respectively at Week 4 ( $p < 0.01$  in both studies).

Of the patients treated with Tyrvaya, the mean change in Schirmer's score was 11.7 mm and 11.3 mm as compared to 3.2 mm and 6.3 mm in the vehicle treated patients in the ONSET-1 study and ONSET-2 study, respectively at Week 4.<sup>3</sup>

**Symptoms:** Symptoms of dry eye disease were measured by mean change from baseline in Eye Dryness Score (EDS).

Please see the press release for additional results.

**Important Safety Information:** The most common adverse reaction reported in 82% of patients was sneezing. In patients who reported sneezing, 98% (281/287) rated it as mild. No patients discontinued Tyrvaya due to sneezing.

Events that were reported in 5-16% of patients were cough, throat irritation, and instillation-site (nose) irritation.<sup>3,6</sup>


## Unwavering Commitment to Patient Access



Oyster Point is committed to supporting the dry eye disease community by supporting access to medication for appropriate patients. The company has launched TEAMTyrvaya™, a free patient support program dedicated to making starting on Tyrvaya as simple as possible for patients.

Benefits include:

- ✓ **Support throughout the insurance process**
- ✓ **Savings and financial help\***
- ✓ **Convenient, free home delivery**



\*For eligible people with commercial insurance.

## References:

1. Market Scope 2016 Dry Eye Products Report: A Global Market Analysis for 2015 to 2021.

2. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. *Am J Ophthalmol.* 2014 Apr;157(4):799-806.

3. Tyrvaya (varenicline solution) Nasal Spray Prescribing Information. Oyster Point Pharma; 2021.

4. Craig JP, Nelson JD, Azar DT, et al. *Ocul Surf.* 2017;15(4):802-812.

5. Bron AJ, de Paiva CS, Chauhan SK, et al. *Ocul Surf.* 2017;15(3):438-5106.

6. Oyster Point Data on File [as of 8/21].

7. Dartt DA, Willcox MD. *Exp Eye Res.* 2013;117:1-3.